NCT05689099View on ClinicalTrials.gov

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Diabetes Mellitus, Type 2Healthy Participants
Interventions
DRUG

Semaglutide B, 1.34 mg/mL

Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

DRUG

Semaglutide B, 0.68 mg/mL

Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.

Trial Locations (1)

90630

Altasciences Clinical LA, Inc., Cypress

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY